# FABPulous

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fabpulous-b-v

- Industry: Medical Devices & Equipment
- Headquarters: Maastricht, Netherlands
- Website: www.fabpulous.com
- Total disclosed funding: $2M
- Latest round: Series B (Feb 5, 2015)
- Investors on record: 6

## About

FABPulous B.V. is a biotechnology company focused on developing innovative fat-based products for research and commercial applications, utilizing proprietary technologies to create sustainable solutions in the health and nutrition sectors.Founded in 2008 in Maastricht, Netherlands, FABPulous B.V. specializes in fat-based technology aimed at enhancing health and nutrition. The company underwent strategic adjustments and secured a Series B funding round on February 5, 2015, raising EUR 1.8 million from investors including Brightlands Venture Partners, Industriebank LIOF, Merck Global Health Innovation Fund, and Thuja Capital. This funding marks their total amount raised to EUR 1.8 million.FABPulous B.V. focuses on producing innovative fat-based products, targeting sectors like health and nutrition. Their proprietary technology enables the development of unique solutions tailored for both research and commercial purposes, serving clients seeking advancements in dietary fats and nutritional enhancements across various markets.FABPulous B.V. generates revenue primarily through the sale of its specialized fat-based products and research services. The company operates under a direct-to-consumer model and engages with corporate clients, facilitating the development of tailored solutions that align with specific health and nutrition objectives.Following its Series B funding round in February 2015, FABPulous B.V. plans to utilize the EUR 1.8 million raised to further advance its research and product development efforts. The company is focusing on launching new fat-based products aimed at the health and nutrition market by the end of 2023. Additionally, FABPulous intends to expand its geographic presence into North America and Asia, targeting these key markets for growth and increased market penetration.

## Funding rounds

- Series B, Feb 5, 2015, $2M — Brightlands Venture Partners, Merck Global Health Innovation Fund, Thuja Capital, Industriebank LIOF
- Series A, Jan 11, 2010 — Brightlands Venture Partners, Capital-C Ventures, Thuja Capital, MeDaVinci Development, Industriebank LIOF

## Investors

- Brightlands Venture Partners (https://capitalatlas.ai/funds/brightlands-venture-partners) — Series A, Series B
- Capital-C Ventures (https://capitalatlas.ai/funds/capital-c-ventures) — Series A
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A, Series B
- MeDaVinci Development — Series A
- Industriebank LIOF (https://capitalatlas.ai/funds/industriebank-liof) — Series A, Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series B